Macy’s Falls on Guidance Despite Sales Beat, Better Outlook

Summary

Bloomberg's Emily Cohn discusses Macy's results: a strong Q2 beat and raised outlook were overshadowed by conservative guidance and high investor expectations. She highlights Macy's push into higher-end retail through Bloomingdale's and Blue Mercury as the growth engine in a K-shaped consumer environment. GLP-1 drug adoption is seen as a developing retail tailwind, and store rationalization remains a key management strategy.

• Macy's Q2 beat and outlook raise were met with conservative guidance against tough prior-year comparisons.
• Investors have high expectations, contributing to the stock's decline.
• Bloomingdale's and Blue Mercury show strength in higher-end segments.
• Macy's is leaning into higher-end consumers with premium products such as real fur and real leather.
• The consumer backdrop is K-shaped: higher-income spending is stronger, while lower-income shoppers are more selective.
• GLP-1 drug use may support apparel demand as consumers need new wardrobes.
• Macy's continues reducing store count and investing in the best-performing locations under Tony Spring's strategy.